Health & Fitness
Health and Fitness
Health and Fitness 
Tue, February 7, 2012
Mon, February 6, 2012
Vermillion to Report Preliminary Results for Fourth Quarter and Fiscal Year 2011 on February 23, 2012
Vermillion to Report Preliminary Results for Fourth Quarter and Fiscal Year 2011... -- AUSTIN, Texas, Feb. 6, 2012 /PRNewswire/ --
Vermillion to Report Preliminary Results for Fourth Quarter and Fiscal Year 2011 on February 23, 2012
Management to Hold Investor Conference Call at 4:30 p.m. ET
AUSTIN, Texas, Feb. 6, 2012 /PRNewswire/ --Vermillion, Inc. (NASDAQ: [ VRML ]), a molecular diagnostics company focusing on oncology and cardiology, plans to report preliminary results for its fourth quarter and fiscal year 2011 on Thursday, February 23, 2012.
Company management will host a conference call at 4:30 p.m. Eastern time on the same day to discuss results for the periods, which ended December 31, 2011. Select preliminary unaudited results will be issued in a press release prior to the call.
Vermillion's president and chief executive officer, Gail Page, will host the call, followed by a question and answer period.
Date: Thursday, February 23, 2012
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-In Number: 1-800-677-8143
International: 1-303-223-2680
Conference ID#: 21576618
The conference call will be broadcast simultaneously [ here ] and available for replay via the investor section of the company's Web site at [ www.vermillion.com ].
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.
A replay of the call will be available approximately two hours after the call and until March 8, 2012.
Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay pin number: 21576618
About Vermillion
Vermillion, Inc. (NASDAQ: [ VRML ]) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its well-known scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found at [ www.vermillion.com ].
Investor Relations:
Liolios Group, Inc.
Ron Both
Tel 949-574-3860
[ Email Contact ]
SOURCE Vermillion, Inc.
[ Back to top ] RELATED LINKS
[ http://www.vermillion.com ]